UNSPSC 51263601: Alfuzosin

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H27N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 90347YTW5F, chemically known as 2-furancarboxamide, n-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro- but generally known as alfuzosin, which bears US NIH Compound Identifier 2092. Alfuzosin comes in base and hydrochloride forms.

UNSPSC 51263601 Alfuzosin is a Commodity code that covers pharmaceutical products, though recent state and local procurement activity under this code shows a significant mismatch between the nominal scope and what is actually being solicited. The single relevant recent opportunity — Seminole County, Florida's IFB for Naloxone and Safe Drug Deactivation Systems — involves emergency medical countermeasures and harm-reduction equipment, not alfuzosin (a urological medication). The Texas HHS Commission's RFI on direct-to-manufacturer prescriptions addresses pharmacy benefit program infrastructure rather than a specific drug product. Neither opportunity aligns with the code's stated pharmaceutical category, suggesting that state and local procurement offices are either applying the code incorrectly or that purchasing activity under alfuzosin specifically is not being tagged in current solicitations.

The issuing-body mix represented in recent postings includes a county health department (Seminole County) and a state health and human services agency (Texas HHS Commission), both seeking to manage pharmaceutical or drug-related procurement through different acquisition mechanisms — an IFB for consumable naloxone kits and an exploratory RFI for pharmacy benefit program redesign. Geographic activity is concentrated in Florida and Texas. The code shows minimal relevant recent activity; current state and local opportunities tagged under UNSPSC 51263601 do not substantiate procurement demand for alfuzosin as a pharmaceutical product line.